tiprankstipranks
Balaji Amines Limited (IN:BALAMINES)
:BALAMINES
India Market
Want to see IN:BALAMINES full AI Analyst Report?

Balaji Amines Limited (BALAMINES) AI Stock Analysis

5 Followers

Top Page

IN:BALAMINES

Balaji Amines Limited

(BALAMINES)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - Gpt-5.6Sol)
Rating:63Neutral
Price Target:
₹2,691.00
▲(17.92% Upside)
Action:Reiterated
Date:09/06/26
The score is anchored by mixed financial performance—strong balance sheet but materially weaker FY2026 free cash flow and cash conversion—partly offset by strong technical uptrend and momentum. Valuation (high P/E with low yield) remains a notable headwind, limiting the overall score despite bullish price action.
Positive Factors
Low leverage
Very low leverage materially reduces financial risk and leaves the company with greater flexibility to fund operations, pursue capacity investment, or absorb weaker industry conditions. The large equity base relative to debt also limits interest and refinancing pressure over the next several quarters.
Negative Factors
Negative free cash flow
A material free-cash-flow deficit reduces the cash available to self-fund growth, dividends, or other capital allocation priorities. Even with low leverage, continued negative free cash flow could increase reliance on balance-sheet resources and make cash generation a key issue over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage materially reduces financial risk and leaves the company with greater flexibility to fund operations, pursue capacity investment, or absorb weaker industry conditions. The large equity base relative to debt also limits interest and refinancing pressure over the next several quarters.
Read all positive factors

Balaji Amines Limited (BALAMINES) vs. iShares MSCI India ETF (INDA)

Balaji Amines Limited Business Overview & Revenue Model

Company Description
Balaji Amines Limited, an Indian company, specializes in the production and global distribution of methylamines, ethylamines, their associated derivatives, alongside a diverse portfolio of specialty chemicals and pharmaceutical excipients. The fir...
How the Company Makes Money
Balaji Amines primarily makes money by manufacturing and selling chemical products—mainly aliphatic amines and amine derivatives—to industrial customers. Its core revenue stream is product sales, where earnings are driven by (a) sales volumes to d...

Balaji Amines Limited Financial Statement Overview

Summary
Overall financials are decent but mixed: profitability is positive (FY2026 gross margin ~34%, net margin ~11.7%) with modest revenue growth returning (~4.4%), and the balance sheet is strong with very low leverage (FY2026 debt-to-equity ~0.07). However, cash-flow quality is a key concern as FY2026 free cash flow turned materially negative (~-1.74B) and cash conversion weakened (operating cash flow covered less than half of net income).
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue15.23B14.25B13.97B16.08B23.38B23.20B
Gross Profit6.07B4.88B4.88B3.50B8.39B8.57B
EBITDA3.52B2.92B2.65B3.53B6.24B6.36B
Net Income2.04B1.67B1.58B2.05B3.26B3.68B
Balance Sheet
Total Assets0.0027.43B22.52B21.46B19.63B18.75B
Cash, Cash Equivalents and Short-Term Investments2.70B2.71B3.50B3.31B3.09B515.37M
Total Debt0.001.33B110.27M196.97M575.74M1.01B
Total Liabilities-21.52B5.91B2.34B2.53B2.65B5.60B
Stockholders Equity21.52B19.76B18.45B17.22B15.54B12.50B
Cash Flow
Free Cash Flow-1.62B-1.74B874.82M704.14M2.62B842.07M
Operating Cash Flow222.05M1.96B2.73B3.34B3.82B2.32B
Investing Cash Flow-1.15B-3.58B-1.61B-1.64B-1.86B-1.47B
Financing Cash Flow-169.00M865.75M-447.73M-749.66M-812.33M-565.13M

Balaji Amines Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2282.15
Price Trends
50DMA
2219.45
Positive
100DMA
1961.35
Positive
200DMA
1534.01
Positive
Market Momentum
MACD
81.87
Negative
RSI
67.75
Neutral
STOCH
82.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Positive. The current price of 2282.15 is above the 20-day moving average (MA) of 2243.20, above the 50-day MA of 2219.45, and above the 200-day MA of 1534.01, indicating a bullish trend. The MACD of 81.87 indicates Negative momentum. The RSI at 67.75 is Neutral, neither overbought nor oversold. The STOCH value of 82.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
₹103.34B46.010.49%5.11%20.64%
64
Neutral
₹9.57B24.650.29%-12.40%-3.04%
63
Neutral
₹81.88B39.760.44%11.08%34.10%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
53
Neutral
₹141.02B80.230.12%51.77%36.94%
53
Neutral
₹108.49B34.850.73%10.96%11.16%
53
Neutral
₹47.82B38.010.17%5.47%24.88%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BALAMINES
Balaji Amines Limited
2,527.15
1,035.94
69.47%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
2,020.50
-2.29
-0.11%
IN:AMNPLST
Amines & Plasticizers Ltd.
174.00
-52.90
-23.31%
IN:ANURAS
Anupam Rasayan India Ltd.
1,238.65
154.20
14.22%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
681.15
-33.28
-4.66%
IN:LXCHEM
Laxmi Organic Industries Ltd.
172.05
-40.59
-19.09%

Balaji Amines Limited Corporate Events

Balaji Amines Clears All Resolutions at 38th AGM, Announces Dividend
Jul 13, 2026
Balaji Amines Limited, a listed chemicals manufacturer known for aliphatic amines and specialty intermediates for pharma and agro industries, continues to operate within India’s regulated capital markets framework. Its governance practices, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2026